FLT3 mutation

News alerts, weekly reports and conference planners

Entrez ID:

2322

Related biomarkers:

‹

›

Related tests:

LeukoStrat® CDx FLT3 Mutation Assay (6)

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline SOHO 2023 - 3 weeks (New C3) venetoclax Sensitive : A2 SOHO 2023 - 3wk	venetoclax Sensitive: A2 - Guideline SOHO 2023 - 3 weeks venetoclax Sensitive : A2 SOHO 2023 - 3 weeks - (New C3)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: D – Preclinical SOHO 2023 - 3 weeks (New D) lintuzumab-Ac225 Sensitive : D SOHO 2023 - 3wk	lintuzumab-Ac225 Sensitive: D – Preclinical SOHO 2023 - 3 weeks lintuzumab-Ac225 Sensitive : D SOHO 2023 - 3 weeks - (New D)
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	venetoclax + gilteritinib Sensitive: D – Preclinical SOHO 2023 - 3 weeks (New D) venetoclax + gilteritinib Sensitive : D SOHO 2023 - 3wk	venetoclax + gilteritinib Sensitive: D – Preclinical SOHO 2023 - 3 weeks venetoclax + gilteritinib Sensitive : D SOHO 2023 - 3 weeks - (New D)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : C1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : C1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : C1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : C1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B	FLT3 inhibitor Sensitive: B - Late Trials FLT3 inhibitor Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : C1	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : C1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B	azacitidine Sensitive: B - Late Trials azacitidine Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria Hypomethylating agent + venetoclax Sensitive : C2	Hypomethylating agent + venetoclax Sensitive: C2 – Inclusion Criteria Hypomethylating agent + venetoclax Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HIA + azacitidine Sensitive: C2 – Inclusion Criteria HIA + azacitidine Sensitive : C2	HIA + azacitidine Sensitive: C2 – Inclusion Criteria HIA + azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HDA + azacitidine Sensitive: C2 – Inclusion Criteria HDA + azacitidine Sensitive : C2	HDA + azacitidine Sensitive: C2 – Inclusion Criteria HDA + azacitidine Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ORY-1001 Sensitive: C2 – Inclusion Criteria ORY-1001 Sensitive : C2	ORY-1001 Sensitive: C2 – Inclusion Criteria ORY-1001 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + sorafenib Sensitive: C3 – Early Trials venetoclax + sorafenib Sensitive : C3	venetoclax + sorafenib Sensitive: C3 – Early Trials venetoclax + sorafenib Sensitive : C3
FLT3 mutation	Non Small Cell Lung Cancer	FLT3 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3	cytarabine + clofarabine Sensitive: C3 – Early Trials cytarabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3

FLT3 mutation

Associations